Divan puts Roche’s US President Donald Trump reiterated plans to reduce the cost of prescription drugs in his recent State of the Union speech, including using closer alignment with international prices. The president said he would “work closely and cooperatively with Congress on a plan that lowers drug prices so we can continue to provide affordable health care for all Americans.” Analysts said the plan would impact the likes of Roche and Bristol-Myers Squibb, which have Part B US sales exposures of 20% and 10%, respectively. Pharma lobby groups warned changes to international price controls would lead to "arbitrary pricing".
US President Donald Trump reiterated plans to reduce the cost of prescription drugs in his recent State of the Union speech, including using closer alignment with international prices. The president said he would “work closely and cooperatively with Congress on a plan that lowers drug prices so we can continue to provide affordable health care for all Americans.” Analysts said the plan would impact the likes of Roche and Bristol-Myers Squibb, which have Part B US sales exposures of 20% and 10%, respectively. Pharma lobby groups warned changes to international price controls would lead to "arbitrary pricing".